Peptomist Founder Warns: US Market Drop May Hit Indian Stocks

STOCK-INVESTMENT-IDEAS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Peptomist Founder Warns: US Market Drop May Hit Indian Stocks
Overview

Jayesh Chandra Gupta, founder of Peptomist LLC, warns Indian stocks could correct if the US market falls. He points to rising oil prices, a weaker rupee, and India's low AI exposure as key risks. Gupta cautions that India isn't immune to global liquidity, energy costs, or foreign investment flows, predicting inflation and advising caution on IT and pharma.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Questionable US Market Rally

Jayesh Chandra Gupta is skeptical of the US stock market's rally since January. He believes it's driven more by speculative call option buying, which forces market makers to purchase stocks and futures to balance their positions. This creates a "gamma squeeze," an artificial boost that can make prices rise quickly but potentially unstably. Peptomist anticipates elevated market stress in the US from mid-May and is positioning for a downturn with long-dated S&P 500 put options and trades linked to the VIX index.

India Faces Inflation Risks from Oil and Rupee

While Indian stocks have shown recent strength, largely due to steady inflows from mutual fund SIPs, Gupta does not expect this outperformance to continue amidst global volatility. He foresees renewed pressure from rising crude oil prices and a weakening rupee. As a major energy importer, India is particularly vulnerable to these shifts. Gupta also notes that with state elections now concluded, the government may have less room to absorb higher fuel costs, potentially passing more of the burden onto consumers. This could fuel inflation and reduce consumer spending.

Sector Outlook: IT, Pharma Cautioned; Infra, Consumer Goods Favored

Gupta is cautious about India's information technology and generic pharmaceutical sectors, both highly dependent on the US market. He argues that Indian IT firms have limited exposure to the global AI ecosystem, and optimism about AI's impact on outsourcing companies is likely overstated. Traditional outsourcing models are under pressure as businesses increasingly use AI for automation. Additionally, Indian generic drug manufacturers might face stricter US regulatory reviews as compliance rules for cheaper imports tighten. Conversely, Gupta remains positive on India's infrastructure sector, anticipating that ongoing government spending and urbanization trends will provide a boost. He also sees potential in companies like cigarette and liquor makers, highlighting their strong pricing ability and consistent consumer demand.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.